Expansion of the SGBP may also be needed to improve coverage of products and services for the treatment of priority health conditions, and remove financial barriers to seeking necessary care. However, any SGBP revision should only provide coverage of interventions shown to be cost-effective. Many OECD countries use Health Technology Assessment (HTA) to inform priority-setting decisions for their benefit packages - for the selection and coverage of medicines and development of standard treatment guidelines most commonly, and increasingly, for non-drug technologies, programmes and services as well.